Tempus AI, Inc. (NASDAQ: TEM), a technology company leading the adoption of AI to advance precision medicine and patient care, today announced that 18 abstracts, including one oral presentation, have been accepted for presentation at the American Association for Cancer Research (AACR) Annual Meeting 2025, on April 25 - 30 in Chicago. Tempus researchers will showcase scientific and clinical research that highlight the transformative impact of AI on oncology treatment and patient outcomes.

“Tempus is proud to showcase a comprehensive collection of scientific research this year, highlighting the impact of our multimodal dataset and AI-enabled diagnostic solutions on cancer research,” said Kate Sasser, PhD, Chief Scientific Officer at Tempus. “AACR stands as a leading forum for cancer research, and we look forward to presenting our findings alongside our collaborators in Tempus’ home city of Chicago.”

Research highlights include:

• Oral Presentation: Investigating the clinical landscape and biological impact of SF3B1 hotspot mutations in breast cancer
  • Date/Time: April 27, 2025; 4:40 PM - 4:45 PM CT
  • Location: To be announced
  • Overview: This study examines the implications of SF3B1 hotspot mutations in breast cancer, focusing on genetic profile, survival outcomes, and biological impacts, by analyzing de-identified data from Tempus’ multimodal real-world database consisting of 420 breast cancer patients with SF3B1 mutations. Innovative genome editing in isogenic breast cell lines revealed that SF3B1 mutations negatively impact cell growth and tumor development. The findings support the utility of SF3B1 mutations as potential therapeutic targets and underscore the importance of understanding their role in cancer biology, with ongoing research aimed at uncovering the mechanisms behind hotspot-specific effects.

• Poster Presentation: Genetic and clinical landscape of NUTM1 structural variants
  • Date/Time: April 28, 2025; 2:00 PM - 5:00 PM CT
  • Location: Section 34
  • Overview: Within Tempus' multimodal real-world database, researchers identified 59 patients with a primary diagnosis of NUT carcinoma—an aggressive cancer—81% of whom had a confirmed NUTM1 fusion. Notably, there were 106 additional patients who had a NUTM1 fusion without a corresponding initial NUT carcinoma diagnosis, suggesting a potentially significant underdiagnosis rate. The study found a variety of fusion gene partners, with certain cancer types showing enrichment of specific fusions. With a median overall survival of just over 5 months, the findings suggest that certain cancer types with a high enrichment of NUTM1 fusions may benefit from universal next-generation sequencing to ensure accurate diagnosis and potentially improve outcomes for patients with high-risk cancer types.

• Poster Presentation: A longitudinal, circulating tumor molecular response biomarker as a predictor of clinical outcomes in a real-world cohort of patients with advanced solid tumors treated with tyrosine kinase inhibitors
  • Date/Time: April 29, 2025; 9:00 AM - 12:00 PM CT
  • Location: Section 45
  • Overview: In a study analyzing advanced cancer patients, researchers evaluated the prognostic value of changes in circulating tumor DNA tumor fraction (ctDNA TF) during tyrosine kinase inhibitor (TKi) therapy. The study, which consisted of 109 patients from Tempus' multimodal real-world database, found that molecular responders had significantly longer real-world overall survival (rwOS) than molecular non-responders across various cancer types. The findings suggest that ctDNA TF may serve as a biomarker to predict molecular response to TKi therapy, potentially guiding treatment decisions and improving patient outcomes in a real-world setting.

• Collaborator-led Poster Presentation: Enhancing TCR-T with a Fas-based switch receptor boosts T cell engraftment, persistence, and anti-tumor activity in models of hard-to-treat PRAME solid tumor indications
  • Date/Time: April 29, 2025; 9:00 AM - 12:00 PM CT
  • Location: Section 39
  • Overview: T-knife Therapeutics is developing a FAS-based switch receptor (FAS-TNFR) to target PRAME-positive solid tumors, designed to enhance T cell activity and overcome the hostile tumor microenvironment. Utilizing Tempus multi-modal data, T-Knife analyzed a large database of tumor samples to identify the inhibitory ligands most frequently found in PRAME-expressing indications and to understand in depth the pattern of expression of PRAME and inhibitory ligands in different patient populations. These insights provided by Tempus were crucial for T-knife to select the optimal switch receptor from their armoring toolbox and determine appropriate target populations for their upcoming clinical trials (Figures 1A, 2D, and 3A-C present Tempus-driven data and insights).

To learn more about Tempus at AACR, click here.

About Tempus

Tempus is a technology company advancing precision medicine through the practical application of artificial intelligence in healthcare. With one of the world’s largest libraries of multimodal data, and an operating system to make that data accessible and useful, Tempus provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics. The goal is for each patient to benefit from the treatment of others who came before by providing physicians with tools that learn as the company gathers more data. For more information, visit tempus.com.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the “Securities Act”), and Section 21E of the Securities Exchange Act of 1934, as amended, about Tempus and Tempus’ industry that involve substantial risks and uncertainties. All statements other than statements of historical facts contained in this press release are forward-looking statements, including, but not limited to, statements regarding the quality of these abstracts; the contributions of these abstracts to the larger scientific community, and the use of Tempus’ products and services to advance clinical care for patients. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “contemplate,” “continue,” “could,” “estimate,” “expect,” “going to,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “should,” “target,” “will,” or “would” or the negative of these words or other similar terms or expressions. Tempus cautions you that the foregoing may not include all of the forward-looking statements made in this press release.

You should not rely on forward-looking statements as predictions of future events. Tempus has based the forward-looking statements contained in this press release primarily on its current expectations and projections about future events and trends that it believes may affect Tempus’ business, financial condition, results of operations and prospects. These forward-looking statements are subject to risks and uncertainties related to: the intended use of Tempus’ products and services; Tempus’ financial performance; the ability to attract and retain customers and partners; managing Tempus’ growth and future expenses; competition and new market entrants; compliance with new laws, regulations and executive actions, including any evolving regulations in the artificial intelligence space; the ability to maintain, protect and enhance Tempus’ intellectual property; the ability to attract and retain qualified team members and key personnel; the ability to repay or refinance outstanding debt, or to access additional financing; future acquisitions, divestitures or investments; including our ability to realize the expected benefits of the acquisition of Deep 6 AI; the potential adverse impact of climate change, natural disasters, health epidemics, macroeconomic conditions, and war or other armed conflict, as well as risks, uncertainties, and other factors described in the section titled “Risk Factors” in Tempus’ Quarterly Report on Form 10-K for the fiscal year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) as well as in other filings Tempus may make with the SEC in the future. In addition, any forward-looking statements contained in this press release are based on assumptions that Tempus believes to be reasonable as of this date. Tempus undertakes no obligation to update any forward-looking statements to reflect events or circumstances after the date of this press release or to reflect new information or the occurrence of unanticipated events, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20250425840107/en/